| Literature DB >> 30273933 |
Thilo Burkard1,2,3, Marten Trendelenburg3,4, Thomas Daikeler3,5, Christoph Hess2,3, Jens Bremerich3,6, Philip Haaf1,3, Peter Buser1,3, Michael J Zellweger1,3.
Abstract
BACKGROUND: In systemic lupus erythematosus (SLE), cardiac manifestations, e.g. coronary artery disease (CAD) and myocarditis are leading causes of morbidity and mortality. The prevalence of subclinical heart disease in SLE is unknown. We studied whether a comprehensive cardiovascular magnetic resonance (CMR) protocol may be useful for early diagnosis of heart disease in SLE patients without known CAD.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30273933 PMCID: PMC6167090 DOI: 10.1371/journal.pone.0202105
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the cohort.
| 83% | |
| 83% | |
| 45 ± 14 | |
| 23.8 ± 6 | |
| • | 36.7% |
| • | 0% |
| • | 33.3% |
| • | 26.7% |
| • | 50% |
| • | 33.3% |
| • | 13.3% |
| • | 33% |
| • | 3.3% |
| • | 10.1 ± 8.1 |
| • | 1.5 [0, 2.5] |
| • | 0 [0, 1] |
| • | 0 [0, 1] |
| • | 5 [4, 6.25] |
| • | 53% |
| • | 50% |
| • | 10% |
| • | 17% |
| • | 73% |
| • | 23% |
| • | 23% |
| • | 30% |
| • | 50% |
| • | 6.7% |
| • | 17% |
| • | 90% |
| • | 83% |
| • | 17% |
| • | 23% |
| • | 118 ± 15 |
| • | 72 ± 13 |
| • | 72 ± 10 |
| • | 10% |
| • | 3.3% |
| • | 3.3% |
| • | 0% |
| • | 10% |
| • | 0% |
| • | 0% |
| • | 3.3% |
Data are given as percentages; mean±SD; median [IQR] as appropriate. ECLAM—European Concensus Lupus Activity Measurement; SLICC/ACR—Systemic Lupus International Collaborative Clinics/American College Rheumatology
ECG parameters and laboratory results of the SLE patients at baseline.
| • | 96.7% |
| • | 3.3% |
| • | 0% |
| • | 154±19 |
| • | 87±15 |
| • | 420±26 |
| • | 6.7% |
| • | 3.3% |
| • | 0% |
| • | 20% |
| • | 32 [21, 58] |
| • | <0.003 [<0.003; 0.055] |
| • | 22% |
Data are given as percentages; mean±SD; median [IQR] as appropriate.
SLE specific treatment at the time of the CMR.
| 56.7% | |
| 76.7% | |
| 3.3% | |
| (3.3%) | |
| (6.7%) | |
| (23.3%) |
Data are given as percentages. SLE–Systemic lupus erythematosus; CMR—cardiovascular magnetic resonance.
Fig 1Structural and functional abnormal CMR findings.
PE–Pericardial effusion; LGE–late gadolinium enhancement; Ischemia indicating stress-perfusion deficit.
Fig 2Frequency and combinations of structural or functional abnormalities in patients with abnormal CMR.
LGE–late gadolinium enhancement; Ischemia indicating stress-perfusion deficit.
Fig 3CMR and coronary angiography in one case with ischemia and coronary artery disease.
A: Short axis stress-perfusion image showing anteroseptal perfusion deficit (arrow). B: Corresponding rest-perfusion. C: Coronary angiography with significant stenoses of the left anterior descending artery including its bifurcation to the diagonal branches (arrows).
Comparison between patients without versus with the presence of LGE on CMR.
| No LGE (n = 21) | LGE (n = 9) | p-value | |
|---|---|---|---|
| 85.7% | 77.8% | 0.223 | |
| 43±14 | 48±15 | 0.449 | |
| • | 52% | 44% | 0.5 |
| • | 29% | 44% | 0.331 |
| • | 14% | 11% | 0.655 |
| • | 28% | 44.4% | 0.398 |
| • | 5% | 0% | 0.7 |
| • | 9.1±6.7 | 12.6±10.5 | 0.476 |
| • | 32 [18;51] | 43 [21;205] | 0.158 |
| • | <0.003 | 0.0034 [<0.003;0.016] | 0.351 |
| • | 9.5% | 33.3% | 0.048 |
Data are given as percentages; mean±SD; median [IQR] as appropriate. LGE–late gadolinium enhancement
Comparison between patients without versus with stress-perfusion deficit on CMR.
| No stress-perfusion deficit (n = 23) | Stress-perfusion deficit (n = 5) | p-value | |
|---|---|---|---|
| 87% | 80% | 0.905 | |
| 43±13 | 47±19 | 0.771 | |
| • | 35% | 20% | 0.521 |
| • | 30% | 20% | 0.640 |
| • | 48% | 60% | 0.622 |
| • | 22% | 80% | 0.011 |
| • | 13% | 0% | 0.393 |
| • | 16% | 60% | 0.141 |
| • | 4.3% | 0 | 0.635 |
| • | 61% | 20% | 0.097 |
| • | 44% | 80% | 0.139 |
| • | 9% | 0% | 0.494 |
| • | 13% | 20% | 0.687 |
| • | 74% | 80% | 0.776 |
| • | 22% | 20% | 0.393 |
| • | 22% | 20% | 0.393 |
| • | 22% | 80% | 0.011 |
| • | 48% | 60% | 0.622 |
| • | 9% | 0% | 0.494 |
| • | 22% | 0% | 0.250 |
| • | 91% | 80% | 0.459 |
| • | 87% | 60% | 0.154 |
| • | 17% | 20% | 0.890 |
| • | 22% | 40% | 0.393 |
| • | 4% | 60% | 0.001 |
| • | 29.3 [15.8;47.8] | 68.6 [28.2;183.7] | 0.033 |
| • | <0.003 [<0.003;0.0032] | 0.006 [<0.003;0.7] | 0.373 |
| • | 13% | 20% | 0.294 |
| • | 23% | 20% | 0.393 |
| • | 68±5 | 63±5 | 0.102 |
| • | 73±12 | 91±17 | 0.027 |
Data are given as percentages; mean±SD; median [IQR] as appropriate. AB–Antibody; ACR–American College Rheumatology; LVEF–left ventricular ejection fraction